Navigation Links
New gene variant identified for nondiabetic end stage renal disease in African-Americans
Date:9/14/2008

Scientists at Johns Hopkins schools of Public Health and Medicine have, for the first time, identified variants in the gene MYH9 that are associated with increased risk for non-diabetic end stage renal disease (ESRD,) which is the near-loss of kidney function leading to either dialysis of transplant. MYH9, located on the 22 chromosome, is the first gene identified for common forms of kidney disease. The study was published online September 14 in the journal Nature Genetics and will be published in the October print edition. In a separate study published in the same issue, researchers at the National Institutes of Health reported similar findings.

In the United States, about 26 million Americans have chronic kidney disease with nearly 427,000 Americans requiring dialysis or kidney transplant each year for the treatment of ESRD, according to U.S. government studies. African Americans are affected disproportionately as they have a four-times-higher incidence of end stage renal disease compared to European Americans.

"We are in the midst of an epidemic of chronic kidney disease, in which African Americans are disproportionately affected. This finding does not mean that non-genetic factors, such as socioeconomic indicators and other factors do not contribute to the higher risk of kidney disease in African Americans. It defines a subset of persons most likely vulnerable to the harmful effect of these factors," said study author Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health.

"Our results show that in addition to environmental and behavioral risk factors, genetic factors play a role as well," said lead author, Linda Kao, PhD, MHS, associate professor in Bloomberg School of Public Health's Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research.

"While we know these genetic variations are common among African Americans, not everyone with the variations has disease and not everyone with disease has the variations. Therefore, it is imperative that we understand what other modifiable risk factors are interacting with the genetic risk factors to cause disease."

For the study, researchers used a technique known as admixture mapping to survey genomes of 1,372 African Americans with ESRD and a control group of about 800 African Americans without ESRD. The study identified several alleles, or variations, in the MYH9 gene that were highly associated with non-diabetic ESRD but not diabetic ESRD. These variants were not associated with diabetic ESRD. Even though the variations identified in this study are present in many populations, they are more frequent among individuals with West African ancestry.

"This finding suggests that the mechanisms leading from onset of chronic kidney disease to kidney failure may differ based on the inciting cause," said study author Rulan S. Parekh, MD, associate professor Johns Hopkins School of Medicine and the Welch Center. "Discovery of the gene and its association with kidney disease will lead to future studies to better understand the biology of kidney disease progression and ultimately may direct drug therapy and potential screening of patients."


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related biology news :

1. Genetic variant increases triglyceride levels in Asian-Americans
2. Genetic variant mimics effect of heart failure medications
3. New vaccine may give long-term defense against deadly bird flu and its variant forms
4. Genetic variants of USF1 are associated with the increased risk for cardiovascular disease
5. Gene variant increases breast cancer risk
6. New genetic variants associated with lipid levels, risk for coronary artery disease
7. Scientists associate 6 new genetic variants with heart disease risk factor
8. Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity
9. Breastfeeding boost IQ in infants with helpful genetic variant
10. New genetic variant associated with prostate cancer in African-Americans
11. Genetic variant linked to odor perception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology: